Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Names Stem Cell Chief; Genomic Health Gains Director; Sequenom to Lose Director; Exagen Taps Beckman Alum for Sales Slot; Affy CFO Becomes VNUS Director; and Others

NEW YORK, April 12 (GenomeWeb News) - Genomic Health has appointed Woodrow Myers to its board of directors. Myers is a director at StanfordUniversityHospitaland visiting adjunct professor of medicine at the UCLA School of Medicine and the former executive vice president and chief medical officer of WellPoint.


Myers is a former health commissioner for New York Cityand Indiana, past chairman of the Visiting Committee for the Harvard School of Public Health, and has served as a member of the Harvard University Board of Overseers and the Stanford University Board of Trustees. He holds medical and business degrees from Harvard and Stanford, respectively.

New River Pharmaceuticals has named John Thottathil its new chief scientific officer. Thottathil will lead the company's research and discovery programs from its laboratories at the Virginia Tech Corporate Research Center.


Thottathil comes to New Riverfrom Abbott Laboratories, where he was director of Core Research and Development in chemistry, in the company's diagnostic division. Before that, he worked at Bristol-Myers Squibb in a variety of positions.


Thottathil holds a PhD in organic chemistry from the Indian Institute of Science in Bangalore, and conducted post-doctoral research at YaleUniversity and at EmoryUniversity in Atlanta, Georgia.

John Lucas will resign from Serquenom's board, according to an SEC filing this week. The effective date of his resignation has not yet been set, and a reason for the move was not given.

Walter Birchmeier has been appointed the new scientific director of the MaxDelbr ck Center for Molecular Medicine Berlin-Buch. The three-year position began Jan. 1. anuary 1, 2006.


Birchmeier is former deputy chairman of the MDC executive board and has served as interim director since April 2004.


He received a PhD in biology from the Universityof Z rich.

NanoInk has hired three senior executives:


  • Jim Whittle has been named vice president of business development. He joins NanoInk from AT Kearney, where he was a member of the Global Healthcare/Lifesciences sector team.


  • Bruce Dudzik has been named senior director of business development. He comes to NanoInk from Affymetrix, where he held posts in research, marketing, and business development.


  • Tom Levesque has been named senior director of global sales. He joins NanoInk from SYNOVA where he held posts in sales and marketing.

David Edwards has joined Stratagene as director of software solutions. In this role, he will manage the company's line of expression and pathways analysis software. Edwards most recently served as director of life sciences at Accelrys.

Pace University presented Howard Cash, president and founder of Gene Codes, with its award for Distinguished Leadership in the Sciences at its 10th annual Dyson Distinguished Achievement Awards in New Yorkthis week.

The Moores Cancer Center at the University of California, San Diego, has named Nicholas Schork, UCSD professor of psychiatry and biostatistics, to lead its center for bioinformatics - a new initiative it has launched that includes UCSD's School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences, the Division of Biological Sciences, the California Institute for Telecommunications and Information Technology, the San Diego Supercomputer Center, the Center for Human Genetics and Genomics, faculty from the departments of mathematics and bioengineering, and other campus departments and resources. Schork is also co-leader of the cancer center's Cancer Genetics Research Program.

Exagen Diagnostics has tapped Thomas O'Connor to the position of vice president of sales.


Prior to joining Exagen, O'Connor held positions as business development manager and North Americasales manager for Beckman Coulter.

VNUS Medical Technologies has appointed Gregory Schiffman to its board of directors. Schiffman, who will also join VNUS' audit committee, is executive vice president and chief financial officer of Affymetrix.

Invitrogen has named former NIH stem cell section chief Mahendra Rao vice president of research of its Stem Cells and Regenerative Medicine business.


Rao holds an MD from BombayUniversity in Indiaand a PhD in developmental neurobiology from the California Institute of Technology.

SeraCare Life Sciences has appointed Cathryn Low as interim chief financial officer.


Low is a turnaround and workout specialist at Prolman Associates, a firm specializing in business turnarounds and management of Chapter 11 bankruptcies. She is expected to serve as interim CFO of SeraCare until a permanent replacement is identified.


She has a BA in biological sciences from Mount Holyoke College and an MBA in finance and accounting from ColumbiaUniversity.

CellCentric hired Tim Fell as chief operating officer. Fell was previously the co-founder of Oxford Gene Technology with Ed Southern, and later became chief technology officer at Arrow Therapeutics.


Fells has a DPhil from Oxford University and an MBA from London Business School.

Xenomics has appointed to its board Colin Foster, former CEO and president of Bayer Pharmaceuticals.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected] to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.